To Assess the Patients' Ability to Self-Administer Fasinumab

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

January 15, 2020

Study Completion Date

December 15, 2020

Conditions
Osteoarthritis, KneeOsteoarthritis, Hip
Interventions
DRUG

Fasinumab AI

Self-administered with auto injector

DRUG

Fasinumab PFS

Prefilled syringe administered by study staff

Trial Locations (23)

11432

Regeneron Research Facility, Jamaica

28401

Regeneron Research Facility, Wilmington

28625

Regeneron Research Facility, Statesville

30342

Regeneron Research Facility, Atlanta

32127

Regeneron Research Facility, Port Orange

32822

Regeneron Research Facility, Orlando

33781

Regeneron Research Facility, Pinellas Park

34471

Regeneron Research Facility, Ocala

37620

Regeneron Research Facility, Bristol

37938

Regeneron Research Facility, Knoxville

40503

Regeneron Research Facility, Lexington

40504

Regeneron Research Facility, Lexington

50265

Regeneron Research Facility, West Des Moines

67205

Regeneron Research Facility, Wichita

73114

Regeneron Research Facility, Oklahoma City

75231

Regeneron Research Facility, Dallas

77024

Regeneron Research Facility, Houston

77089

Regeneron Research Facility, Houston

77804

Regeneron Research Facility, Houston

80033

Regeneron Research Facility, Wheat Ridge

85297

Regeneron Research Facility, Gilbert

85307

Regeneron Research Facility, Glendale

90029

Regeneron Research Facility, Los Angeles

All Listed Sponsors
collaborator

Teva Pharmaceutical Industries, Ltd.

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03491904 - To Assess the Patients' Ability to Self-Administer Fasinumab | Biotech Hunter | Biotech Hunter